Old Web
English
Sign In
Acemap
>
authorDetail
>
Sanjeev Roy
Sanjeev Roy
Merck KGaA
Medicine
Multiple sclerosis
in patient
Cladribine
Internal medicine
4
Papers
10
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Baseline Serum Neurofilament Light Chain Levels Predict Conversion to McDonald 2005 Multiple Sclerosis (MS) Within 2 Years of a First Clinical Demyelinating Event in Patients with MS (1908)
2021
Neurology
Jens Kuhle
David Leppert
Giancarlo Comi
Nicola De Stefano
Ludwig Kappos
Mark S. Freedman
Delphine Issard
Sanjeev Roy
Show All
Source
Cite
Save
Citations (0)
Reduction in CUA MRI Lesions in the First 6 Months after Cladribine Tablets Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS Subgroup Analysis (1921)
2021
Neurology
Nicola De Stefano
Frederik Barkhof
Xavier Montalban
Anat Achiron
Tobias Derfuss
Andrew T. Chan
Suzanne Hodgkinson
Alexandre Prat
Letizia Leocani
Klaus Schmierer
Finn Sellebjerg
Patrick Vermersch
Heinz Wiendl
B. Keller
Sanjeev Roy
Show All
Source
Cite
Save
Citations (0)
Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).
2020
Therapeutic Advances in Neurological Disorders
Francesco Patti
Andrea Visconti
Antonio Capacchione
Sanjeev Roy
Maria Trojano
Show All
Source
Cite
Save
Citations (10)
A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY-MS Baseline Analysis (1487)
2020
Neurology
Nicola De Stefano
Anat Achiron
Frederik Barkhof
Andrew T. Chan
Tobias Derfuss
Suzanne Hodgkinson
Letizia Leocani
Xavier Montalban
Alexandre Prat
Klaus Schmierer
Finn Sellebjerg
Patrick Vermersch
Heinz Wiendl
B. Keller
Sanjeev Roy
Show All
Source
Cite
Save
Citations (0)
1